Mounjaro and Trulicity are two injectable medications that treat type 2 diabetes. Learn more about their key similarities, ...

Weight loss clinics, telehealth companies, physicians, and pharmacies that have been prescribing or dispensing compounded GLP ...

Eli Lilly launches diabetes and obesity drug Mounjaro in India, offering innovative treatment for metabolic health management ...

GPs are free to prescribe semaglutide to all eligible patients in line with NICE guidelines after long-term shortages have been resolved.

For kidney transplant recipients with type 2 diabetes, use of glucagon-like peptide-1 receptor agonists was associated with ...

US pharma giant Eli Lilly's Mounjaro can prove crucial in treatment of obesity & type 2 diabetes. Launched in the US in 2022, ...

Eli Lilly's much-anticipated drug for diabetes and obesity, that competes with Ozempic globally, is now in India. Here's what ...

SAN DIEGO -- Two retrospective studies hinted at potential negative effects of GLP-1 receptor agonists for patients requiring ...

Semaglutide use in patients with type 2 diabetes moderately increases the risk of nonarteritic anterior ischemic optic neuropathy.

The "Liraglutide and Semaglutide Market by Type, by Route of Administration, by Application, by Distribution Channel, and by Region" report has been added to ResearchAndMarkets.com's offering. The ...

(Circulation: Cardiovascular Interventions) Use of the GLP-1 drug dulaglutide (Trulicity) during a smoking cessation program resulted in initial reductions in body weight and blood pressure ...